Skip to main content
. 2023 Aug 10;10(8):ofad369. doi: 10.1093/ofid/ofad369

Figure 2.

Figure 2.

Anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain serum antibody responses and neutralizing antibody levels among participants with cystic fibrosis without lung transplantation (n = 5), lung transplant recipients (n = 16), and healthy controls (n = 9). A, Immunoglobulin levels in patients with cystic fibrosis, lung transplant, and healthy controls at each time point. B, Neutralization activity by pseudovirus neutralization assay of serum at 24 weeks after primary 2-dose vaccination series. Abbreviation: ID50, median infective dose. C–H, Neutralization activity in patients with cystic fibrosis, lung transplant recipients, and healthy controls at each time point against the ancestral (D614) SARS-CoV-2 strain (C) and the variants Alpha (B.1.1.7) (D), Beta (B.1.351) (E), Gamma (P1) (F), Delta (B.1.617.2) (G), and Omicron (B.1.1.529) (H). Pairwise comparisons were performed using Mann-Whitney tests. Box plots show 25th, 50th, and 75th percentiles; whiskers, maximum and minimum. *P < .05; **P < .01; ***P < .001; NS, not significant. All data points are shown; y-axes are in logarithmic scale.